Bank of New York Mellon Corp Sells 28,753 Shares of Envista Holdings Co. (NYSE:NVST)

Bank of New York Mellon Corp reduced its stake in shares of Envista Holdings Co. (NYSE:NVST - Free Report) by 2.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,362,534 shares of the company's stock after selling 28,753 shares during the quarter. Bank of New York Mellon Corp owned 0.79% of Envista worth $26,283,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in NVST. Huntington National Bank increased its position in Envista by 97.8% in the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company's stock valued at $38,000 after acquiring an additional 949 shares in the last quarter. Venturi Wealth Management LLC raised its position in Envista by 528.4% in the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company's stock worth $38,000 after purchasing an additional 1,638 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Envista by 30.5% during the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company's stock worth $44,000 after acquiring an additional 538 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Envista during the 4th quarter valued at about $53,000. Finally, US Bancorp DE boosted its stake in Envista by 150.6% in the third quarter. US Bancorp DE now owns 4,971 shares of the company's stock valued at $98,000 after acquiring an additional 2,987 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on NVST shares. JPMorgan Chase & Co. decreased their target price on Envista from $20.00 to $19.00 and set a "neutral" rating for the company in a research report on Thursday, March 6th. Needham & Company LLC reissued a "hold" rating on shares of Envista in a research report on Thursday, March 6th. New Street Research set a $19.00 target price on Envista in a report on Thursday, March 6th. UBS Group decreased their price objective on Envista from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Monday. Finally, Morgan Stanley cut their target price on Envista from $20.00 to $19.00 and set an "equal weight" rating on the stock in a research note on Thursday, March 6th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $20.18.

Remove Ads

Envista Stock Performance

Shares of NVST stock traded down $0.53 on Thursday, reaching $16.21. The stock had a trading volume of 2,148,541 shares, compared to its average volume of 2,288,634. The firm's 50-day moving average is $20.10 and its two-hundred day moving average is $19.67. The firm has a market capitalization of $2.79 billion, a price-to-earnings ratio of -2.50, a P/E/G ratio of 1.27 and a beta of 1.33. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. Envista Holdings Co. has a 12 month low of $15.15 and a 12 month high of $23.00.

Envista (NYSE:NVST - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, research analysts expect that Envista Holdings Co. will post 1 EPS for the current fiscal year.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.